Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03733678
Other study ID # LARCs-2018
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 23, 2021
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source World Bank
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey. The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers. The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2500
Est. completion date December 31, 2024
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 10 Years to 49 Years
Eligibility Inclusion Criteria: - Female - Ages 10-49 - Presenting at HGOPY seeking FP counseling/services - HGOPY clients referred to the family planning unit for consultation Exclusion Criteria: * No exclusion criteria

Study Design


Intervention

Behavioral:
Price discounts for SARCs
SARCs are offered free to the client
Price discounts for LARCs
LARCs are offered at lower prices to the client
Sequential vs. simultaneous recommendations
Top ranked methods are presented to the client sequentially or simultaneously

Locations

Country Name City State
Cameroon Hôpital gynéco-obstétrique et pédiatrique de Yaoundé (HGOPY) Yaoundé

Sponsors (6)

Lead Sponsor Collaborator
World Bank George Washington University, Stanford University, University of California, San Diego, University of Exeter, Yaounde Gynecology, Obstetrics and Pediatrics Hospital

Country where clinical trial is conducted

Cameroon, 

Outcome

Type Measure Description Time frame Safety issue
Primary The client adopted a LARC using data from the counseling sessions 1-day
Primary The client adopted a modern contraceptive method (LARC or SARC) using data from the counseling sessions 1-day
Secondary Was the client treated with respect by the provider during the counseling session? Self-reported indicator variable using follow-up surveys two weeks after counseling session 2-weeks
Secondary Did the client trust the provider during the counseling session? Self-reported indicator variable using follow-up surveys two weeks after counseling session 2-weeks
Secondary Did the health provider give information about contraceptive methods that was easy to understand during the counseling session? Self-reported indicator variable using follow-up surveys two weeks after counseling session 2-weeks
Secondary Client satisfaction with adopted contraceptive method using 2-week and 16-week follow-up surveys 2-week and 16-week measurements
Secondary Discontinuation of adopted contraceptive method using 2-week, 16-week, and 52-week follow-up surveys 2-week, 16-week, and 52-week measurements
Secondary Percentage of participants with unintended pregnancy within the time frame using 16-week and 52-week follow-up surveys 16-week and 52-week measurements
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A